Reviews/Chronic Pain Pharmacotherapy/Nav1.8 inhibition in neuropathic pain
Nov · CPP-NOV-02 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
The claim asks whether blocking the Nav1.8 pain channel lowers nerve-injury (neuropathic) pain in human trials. In this body of evidence, the one drug that blocks Nav1.8 selectively (suzetrigine) was only tested in human trials for short-term pain after surgery, where it beat placebo [23][6], not for neuropathic pain. The human neuropathic-pain trials that are present used older drugs that hit several sodium channels at once, so any benefit cannot be pinned on Nav1.8 specifically [22][27]. A human experiment that blocked Nav1.8 on its own found no meaningful pain reduction [25]. The evidence that Nav1.8 blockade helps neuropathic pain comes only from animals and cells [28][39][37][9], so the exact claim, as stated for clinical trials, is not carried by this evidence.
A selective Nav1.8 inhibitor reduces pain versus placebo in phase 3 trials, but only in moderate-to-severe acute postoperative pain after abdominoplasty and bunionectomy [23] and in mixed surgical and non-surgical acute pain [6]. The neuropathic-pain clinical trials in this corpus use non-selective agents: lacosamide, which 'acts on Nav1.3, Nav1.7, and Nav1.8' [22], and oxcarbazepine [27]. Direct Nav1.8-targeted evidence in neuropathic models is animal or in vitro only: antisense knockdown in rats [28], ambroxol in rat neuropathic models [39], Nav1.8-expressing neuron ablation reducing cold allodynia in mice [37], and a dynamic-clamp neuropathic model [9]. A human crossover trial reported that pain was 'not reduced to a relevant extent' by Nav1.8 inhibition alone [25], and [17] attributes 'incomplete analgesia produced by even the largest concentrations of VX-548 in clinical studies' to residual firing. The contested point: The division is on the word 'clinical': the selective Nav1.8 trials are in the wrong indication (acute, [23][6]) while the neuropathic trials use the wrong, non-selective intervention ([22][27]), and the two conditions never coincide in any single study. An included source notes phase II Nav1.8 trials gave 'modest' results [29], and no corpus paper shows selective Nav1.8 inhibition reducing neuropathic pain in a clinical trial.
All 41 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Pain Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Indication mismatch: the only selective Nav1.8 inhibitor clinical trials in the corpus ([23], [6]) are in moderate-to-severe ACUTE postoperative pain (abdominoplasty, bunionectomy, mixed surgical/non-surgical), not neuropathic pain. The claim's outcome — neuropathic pain reduction — has not been demonstrated clinically for selective Nav1.8 inhibition.
Confounded attribution: the corpus's neuropathic-pain clinical trials ([22] lacosamide, [27] oxcarbazepine) use NON-selective sodium-channel drugs — lacosamide explicitly 'acts on Nav1.3, Nav1.7, and Nav1.8' — so any benefit cannot be attributed to Nav1.8 inhibition specifically.
Where it remains uncertain. Nav1.8-specific neuropathic evidence is preclinical only [28][39][37], while a human study found Nav1.8 inhibition alone gave no relevant pain reduction [25].
Aleatory
Oxcarbazepine's effect in neuropathic pain varied by nociceptor phenotype [27], so patient-level variability in who responds is intrinsic, not just a measurement gap.
Epistemic
The corpus contains no clinical trial testing a selective Nav1.8 inhibitor in a neuropathic indication, so the claim's exact setting is simply unstudied here.
Inferential
Benefit in [22] lacosamide and [27] oxcarbazepine cannot be inferred as Nav1.8-specific because these agents act on multiple channels.
The load-bearing papers from a corpus of 41, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Confirms selective Nav1.8 clinical efficacy is established for acute pain only.
“In the largest randomized, controlled phase 3 trials in established acute pain models, suzetrigine monotherapy demonstrated statistically significant and clinically meaningful reduction in moderate-to-severe acute pain compared to placebo.”
Panel auditInternal validity: low · scope of inference: Safety and perceived effectiveness of suzetrigine in acute pain.Key limitations: acute not neuropathic · single-arm, no control
The neuropathic-pain clinical trial here uses a NON-selective agent; its benefit cannot be attributed to Nav1.8 inhibition.
“In 58.3% of patients receiving lacosamide, mean average pain decreased by at least 1 point, compared to 21.7% in the placebo group”
Panel auditInternal validity: medium · scope of inference: Lacosamide in Nav1.7-related small fibre neuropathy.Key limitations: non-selective (Nav1.3/1.7/1.8) so not Nav1.8-specific · small n · Nav1.7-mutation population
Strongest selective-Nav1.8 clinical trial evidence, but the indication is ACUTE pain, not neuropathic — does not satisfy the claim's outcome.
“two phase 3, randomized, double-blind, placebo- and active-controlled trials were conducted in adults with moderate-to-severe acute pain on the verbal categorical rating scale and 4 or greater on the numeric pain rating scale after abdominoplasty (n = 1,118) or bunionectomy (n = 1,073)”
Panel auditInternal validity: high · scope of inference: Suzetrigine for moderate-to-severe acute pain after abdominoplasty or bunionectomy.Key limitations: acute not neuropathic · did not beat active comparator
Mechanistic dose-response context in a neuropathic genetic model; in vitro.
“suggests, more generally, that full inhibition of Nav1.8 may not be required for relief of pain due to DRG neuron hyperexcitability”
Panel auditInternal validity: not assessable from abstract · scope of inference: Nav1.8's contribution to DRG neuron excitability in an inherited-erythromelalgia model.Key limitations: in vitro only · excitability proxy not pain · suggests full inhibition may not be needed
4 of 41 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The exact claim is not carried by the corpus: selective-inhibitor clinical trials are in the wrong indication (acute), neuropathic clinical trials use the wrong (non-selective) intervention, and the on-target neuropathic evidence is non-clinical.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Selective Nav1.8 inhibitor trial in neuropathic pain. The claim's exact intervention-outcome-setting combination is absent; selective trials are acute [23][6] and neuropathic trials are non-selective [22][27]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Randomized placebo-controlled trial of a selective Nav1.8 inhibitor (e.g. suzetrigine) in a defined neuropathic population such as diabetic peripheral neuropathy or postherpetic neuralgia, with a validated pain endpoint.
Open question: Does a selective Nav1.8 inhibitor reduce neuropathic pain in a clinical trial? Why it is still open: Every selective-inhibitor clinical trial in the corpus is in acute pain [23][6]; no neuropathic clinical trial uses a selective Nav1.8 inhibitor.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19